August 11, 2011 – Arisaph Pharmaceuticals and Royalty Pharma Announce Monetization and Amendment of DPP-IV License Agreement
// view PDF

March 18, 2011 – FDA Accepts Investigational New Drug Application for ARI-3037MO; First in Man Clinical Trial Set to Begin During First Quarter of 2011
// view PDF

June 8, 2008 – Arisaph Pharmaceuticals Announces at the ADA That Its Potent DPP 4 Inhibitor (ARI-2243) Possesses an Additional Mechanism That Contributes to Improved Glucose Control.
// view PDF

March 11, 2008 – FDA Accepts Investigational New Drug Application for ARI-2243and a First in Man Clinical Trial Set to Begin During the First Half of 2008.
// view PDF

June 25, 2007 – Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-IV Inhibitor, ARI-2243, at the ADA.
// view PDF

August 9, 2006 – Arisaph Pharmaceuticals Announces Second Closing of $8 Million Equity Investment.
// view PDF

June 30, 2006 – Dr. Antonio Gotto, Jr. to Join Board of Directors And Scientific Advisory Board of Arisaph Pharmaceuticals.
// view PDF

June 30, 2006 – Arisaph Pharmaceuticals Announces Appointments of Scientific Advisory Board Members.
// view PDF

February 24, 2006 – Arisaph Pharmaceuticals Grants Non-Exclusive License Under Dipeptidyl Peptidase (DPP-IV) Patents.
// view PDF

November 14, 2005 – Arisaph Reports On Promising Results Presented At AHA: Novel APO A-I Mimetic Peptide Significantly Inhibits Atherosclerosis In Precinical Animal Study.
// view PDF

November 14, 2005 – Triad Pharmaceuticals Adopts New Name of Arisaph Pharmaceuticals.
// view PDF